Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2000

View Archived Issues

Clinical trials continue to support the utility of Merck's new coxib MK-0663

Swiss researchers identify CGA-137053 as potential next-generation Tat inhibitor

Small-molecule CXCR4 antagonist shows potential as new anti-AIDS drug

Acute LU-135252 produces hemodynamic improvement without neurohumoral stimulation in CHF

Imperial College Innovations launches company for allergy therapies

Sepracor reports progress in ICE development

Limited effects of chronic thyroxine on clinical PK of talinolol

Preliminary clinical results for new benzodiazepine do not support preclinical findings

Novartis continues with European launch of Trileptal

Galenica and Memorial Sloan-Kettering initiate phase I trial of prostate cancer treatment

Favorable safety and efficacy profile seen for IQB-9302 in early clinical trial

Genasense shown to enhance activity of chemotherapy in mouse model of breast cancer

Methotrexate conjugates with utility in psoriasis reported by CSIRO

New bile acid transport inhibitors synthesized at Sankyo and tested for biological activity

U.S. and Italian researchers team up to design new beta-lactamase inhibitors

Novel paroxetine derivative and salts patented by SB

Preparation and use of new lactams as inhibitors of serine proteases, antibiotics

Piperazine-based tachykinin receptor antagonists identified by Fujisawa

Optically active compound discovered by Biorex to exert positive inotropic effects

NK1 antagonist inhibits acute and delayed cisplatin-induced emesis in ferrets

Status of Glaxo Wellcome and SmithKline Beecham merger updated

Taiho's novel anticancer therapy licensed to SB

Benefits of IL-2 revealed in phase II trial in HIV-infected patients

Antibiotic demonstrates efficacy in mouse model of Huntington's disease

Paladin to market Aptosyn in Canada

Licensing opportunity from NIH: newly isolated cancer therapy target gene

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...